**Drug Implementation Advice: Proposed Scope**

Icatibant for the treatment of acute attacks of hereditary angioedema (HAE) with normal C1-inhibitor (HAE nC1-INH)

BACKGROUND

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada’s provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the *Canadian Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.

At the request of participating publicly-funded drug programs, an Implementation Advice Panel (IAP) is being convened to advise the drug programs on reimbursement criteria for icatibant for the treatment of acute attacks of hereditary angioedema (HAE) with normal C1-inhibitor (HAE nC1-INH). Appendix 1 lists the drug reimbursement recommendations for icatibant. This document outlines a draft scope for to inform panel discussions, including which drugs are under consideration and questions to be addressed by the panel.

# OBJECTIVES

The panel will be comprised of specialists in Canada with expertise in the diagnosis and management of patients with HAE. In addition to the clinical panelists and staff, representatives from public drug programs will be invited to participate in the discussion as well as provide input in advance of the meeting on discussion points for the panel. For more information on the implementation advice process, please refer to the [Procedures for Implementation Advice for Health Technologies.](https://www.cadth.ca/sites/default/files/Drug_Review_Process/CADTH_Procedures_for_Implementation_Advice_for_Health_Technologies.pdf)

The Formulary Working Group (FWG) are requesting implementation guidance on the following questions:

1. Which subpopulation of patients with normal C1-inhibitor (HAE nC1-INH) would benefit most from access to icatibant? What specific clinical criteria should they possess?
2. Should the treatment approach for acute attacks for patients with type III HAE be aligned with the treatment of acute attacks for patients with HAE types I/II?
3. Based on the currently available data regarding the efficacy and safety of berinert and icatibant, what factors should be considered when deciding between both drugs (irrespective of the mode of administration)?
   1. If both berinert and icatibant are deemed standard treatment options for Type III HAE, is there a sub-group of patients who would benefit most from treatment with icatibant?
   2. If a sub-group of patients can be identified, which patients (e.g. those with laryngeal vs. non-laryngeal symptoms) may benefit more from icatibant?

# OPPORTUNITIES FOR STAKEHOLDER INPUT

We welcome input from patient and clinician groups as well as manufacturers whose product(s) may be impacted by the implementation advice. All external partners are invited to provide comments and/or complementary information using the [Input template for Implementation Advice](https://www.cadth.ca/sites/default/files/Drug_Review_Process/CADTH_Implementation_Advice_Template.docx). This input will be considered by the implementation advice panel in their deliberations.

# OPPORTUNITIES FOR FEEDBACK ON DRAFT ADVICE

When ready, draft implementation advice will be posted for feedback on our website. At that time eligible external partners are welcome to provide feedback on the draft advice using the [Feedback on Draft Implementation Advice Report template.](https://www.cadth.ca/sites/default/files/Drug_Review_Process/CADTH_Feedback_Draft_Advice_Template.docx)

# DRUGS IN SCOPE FOR IMPLEMENTATION ADVICE

**Table 1: Currently Marketed Icatibant Products and Approved Indications**

|  |  |  |
| --- | --- | --- |
| **Drug** | **Brand** | **Approved Indication** |
| Icatibant | Firazyr | Icatibant Injection (icatibant acetate) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older with C1-esterase inhibitor deficiency.  Icatibant Injection is supplied through a controlled distribution program that is accessed by patients and pharmacies. Patients or a caregiver should be trained in subcutaneous injection techniques under the guidance of a healthcare professional before they can administer Icatibant Injection (see DOSAGE AND ADMINISTRATION).  Geriatrics (> 65 years of age): Limited information is available regarding the use of icatibant acetate in patients older than 65 years of age (see WARNINGS AND PRECAUTIONS and ACTION AND CLINICAL PHARMACOLOGY, Pharmacokinetics).  Pediatrics (<18 years of age): Icatibant Injection is indicated for use in adolescents and children aged 2 years and older. Studies in children aged less than 2 years or weighing less than 12 kg have not been performed. No dosage regimen can be recommended in children aged less than two years or weighing less than 12 kg as the safety and efficacy have not been established.  ***Please Note****: use of icatibant for the treatment acute attacks of hereditary angioedema (HAE) with normal C1-inhibitor (HAE nC1-INH) is considered off-label use* |
| C1 Esterase Inhibitor | Berinert® 500/Berinert® 1500 | Berinert (C1 Esterase Inhibitor, Human) is indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) of moderate to severe intensity\* in pediatric and adult patients. |
| Generics products: | * ACCORD Healthcare Inc: Icatibant Injection * JUNO Pharmaceuticals Corp: Icatibant Injection * JAMP Pharma Corporation: Icatibant Injection * MINT Pharmaceuticals Inc: Mint-Icatibant * TEVA Canada Limited: Teva-Icatibant | |

*Source: Drug Product Monograph, May 17, 2024; JAMP Pharma Corporation*

# APPENDICES

## Appendix 1: CADTH Recommendations on icatibant for the treatment of acute attacks of hereditary angioedema (HAE) with normal C1-inhibitor (HAE nC1-INH)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug** | **Brand** | **Indication** | **CDEC Recommendation** | **Final Rec. Date** |
| **Icatibant** | Firazyr | HAE nC1-INH | No recommendations were issued |  |
| **Icatibant** | Firazyr | For routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adult (Type I/II) | Reimburse with clinical criteria and/or conditions | November 19, 2019 |